Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.
Chris T. Hyder, EVP—Group President, Health & Hygiene at The Clorox Company (CLX), reported an equity award conversion on 09/16/2025. The filing shows the acquisition of 7,208 shares of Clorox common stock at an indicated price of $124.85 per share, bringing his total beneficial ownership to 29,325 shares. The shares arise from Restricted Stock Units that vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025. This disclosure records an insider share increase tied to compensation rather than an open-market purchase.
Nina Barton, Executive Vice President and Group President - Care & Connections at The Clorox Company (CLX), reported an acquisition on 09/16/2025 of 7,208 shares of Clorox common stock at a reported price of $124.85 per share, increasing her beneficial ownership to 28,496 shares. The filing indicates these shares are restricted stock units that will vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The Form 4 was submitted by attorney-in-fact Jinho Joo on 09/18/2025.
Eric H. Reynolds, EVP and Chief Operating Officer of The Clorox Company (CLX), reported an acquisition of company common stock on 09/16/2025. The Form 4 shows an acquisition of 9,611 shares at a price of $124.85 per share, bringing his beneficial ownership to 63,832 shares following the transaction. The filing also discloses Restricted Stock Units that vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The form was signed by an attorney-in-fact on 09/18/2025.
Luc Bellet, EVP and Chief Financial Officer of The Clorox Company (CLX), reported an open-market purchase of 7,368 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the purchase, the filing shows Mr. Bellet beneficially owned 19,546 shares. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
The filing also discloses restricted stock units that will vest in four equal installments on October 5, 2026, October 5, 2027, October 5, 2028, and October 5, 2029. No derivative transactions, dispositions, or additional cash- or price-related terms beyond the reported purchase price are included in the document.
Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Eric H. Reynolds, Executive Vice President and Chief Operating Officer of The Clorox Company (CLX), reported transactions dated 09/04/2025. The filing shows an exercise of stock options (derivative) to acquire 15,210 shares at an exercise/conversion price of $111.60, and a related non-derivative acquisition of 15,210 shares (reported at $111.60). The report also discloses a sale of 15,041 shares at a weighted average price of $123.7848 (trade prices ranged $123.731–$123.84). Following these transactions the reporting person is shown as beneficially owning 69,262 shares after the acquisition and 54,221 shares after the sale. The form is signed by an attorney-in-fact on 09/08/2025.
Clorox Company (CLX) Form 144 notice reports a proposed sale of 15,041 shares of Common stock through UBS Financial Services on the NYSE with an aggregate market value of $1,861,847.74. The filing shows the shares were acquired and are proposed to be sold on 09/04/2025 following an employee stock option exercise paid in cash. The filer states there have been no securities sold by the account in the past three months and affirms no undisclosed material adverse information is known. The form is a routine Rule 144 notice documenting the intended compliant sale.
The Clorox Company reported fiscal 2025 net sales of $7.1 billion and employed about 7,600 people worldwide. Net sales were essentially flat for the year while the company grew overall market share and expanded gross margin. Diluted net earnings per share rose 190%, driven largely by the absence of prior-period Argentina divestiture losses and a prior pension settlement charge, together with higher current‑period volume, cost savings and cyberattack insurance recoveries, partially offset by the loss on the divestiture of the Better Health VMS business, unfavorable mix and higher trade promotion spending.
Clorox completed the Better Health VMS divestiture in September 2024, is winding down the Glad venture with P&G (P&G’s 20% to be acquired by Clorox at fair market value upon termination), and continues a multi‑year transformational program including ERP and digital investments with total incremental spend expected to be $570–$580 million. The company paid $602 million in dividends in FY2025 and announced a 2% dividend increase in July 2025. Key concentrations and metrics disclosed include >80% of sales from brands ranking No.1 or No.2 in category, product-line mix (Cleaning 44%, Bags & Wraps 15%, Food 12%, Cat Litter 10%), and Walmart accounting for 27% of consolidated net sales.